1FME Stock Overview Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteFresenius Medical Care AG Competitors Price History & Performance
Summary of share price highs, lows and changes for Fresenius Medical Care Historical stock prices Current Share Price €44.88 52 Week High €46.00 52 Week Low €32.64 Beta 0.84 1 Month Change 7.55% 3 Month Change 20.45% 1 Year Change 17.98% 3 Year Change -17.50% 5 Year Change -30.07% Change since IPO -43.26%
Recent News & Updates
New minor risk - Financial position Nov 07
Third quarter 2024 earnings released: EPS: €0.73 (vs €0.29 in 3Q 2023) Nov 06
Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025 Nov 05 Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025 Nov 01
Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025 Aug 08
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01 See more updates
New minor risk - Financial position Nov 07
Third quarter 2024 earnings released: EPS: €0.73 (vs €0.29 in 3Q 2023) Nov 06
Fresenius Medical Care AG to Report Q2, 2025 Results on Aug 05, 2025 Nov 05 Fresenius Medical Care AG to Report Q1, 2025 Results on May 06, 2025 Nov 01
Fresenius Medical Care AG to Report Q4, 2024 Results on Feb 25, 2025 Aug 08
Fresenius Medical Care AG Confirms Earnings Guidance for the Fiscal Year 2024 Aug 01
Second quarter 2024 earnings released: EPS: €0.64 (vs €0.48 in 2Q 2023) Jul 31
Upcoming dividend of €1.19 per share May 10
New minor risk - Financial position May 09
Fresenius Medical Care Ag Confirms Earnings Guidance for the Fiscal Year 2024 May 08
First quarter 2024 earnings released: EPS: €0.24 (vs €0.29 in 1Q 2023) May 07
Fresenius Medical Care Launches Augmented Reality for Training on Kidney Replacement Therapy Device Mar 19 Fresenius Medical Care AG Appoints Jörg Häring as New Global Head of Legal, Compliance and Human Resources and Also Assume the Role of Labor Director, Effective from June 1, 2024 Mar 13
Full year 2023 earnings released: EPS: €1.70 (vs €2.30 in FY 2022) Feb 22
Dividend increased to €1.19 Feb 22
Fresenius Medical Care AG Proposes Dividend for the Fiscal Year 2023 Feb 21 Fresenius Medical Care AG Provides Earnings Guidance for Fiscal Year 2024 Feb 20
Fresenius Medical Care Brings Dialysis Therapy to Kidney Disease Patients in the U.S Feb 09
Fresenius Medical Care Enters into Favorable Settlement Agreement with U. S. Government Nov 23 Fresenius Medical Care AG & Co. Revises Earnings Guidance for the Year 2023
New minor risk - Earnings quality Nov 15 Fresenius Medical Care AG & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 22, 2024 Nov 07
An Unknown buyer entered into an agreement to acquire National Cardiovascular Partners, LP from Fresenius Medical Care AG & Co. KGaA (XTRA:FME) Nov 03
Third quarter 2023 earnings released: EPS: €0.29 (vs €0.78 in 3Q 2022) Nov 02 Fresenius Medical Care AG & Co. KGaA to Report Q1, 2024 Results on May 07, 2024 Fresenius Medical Care Appoints Craig Cordola as New Management Board Member for Care Delivery Nov 01
Fresenius Medical Care Achieves Key Ai Milestone with First-Phase Completion of Largest Global Dialysis Clinical Dataset Oct 27
New minor risk - Share price stability Oct 11
Investor sentiment deteriorates as stock falls 17% Oct 11 Fresenius Medical Care Announces Fda Clearance of Versi(R)Hd with Guideme Software Aug 24
New minor risk - Financial position Aug 04
Second quarter 2023 earnings released: EPS: €0.48 (vs €0.50 in 2Q 2022) Aug 03 An unknown buyer acquired Local dialysis service provider business from Fresenius Medical Care AG & Co. KGaA (XTRA:FME).
New minor risk - Share price stability Jul 13
Fresenius Medical Care Announces Executive Changes Jul 11
Fresenius Medical Care participated Announces Breakthrough Study Demonstrates That High-Dose Hemodiafiltration Treatment for Kidney Failure Patients Significantly Reduces Mortality Rates Jun 21
First quarter 2023 earnings released: EPS: €0.29 (vs €0.54 in 1Q 2022) May 10
Upcoming dividend of €1.12 per share at 2.5% yield May 10
Full year 2022 earnings released: EPS: €2.30 (vs €3.31 in FY 2021) Feb 22 Fresenius Medical Care AG & Co. KGaA Announces CEO Changes Dec 06
Fresenius Medical Care AG & Co. KGaA, Annual General Meeting, May 16, 2023 Nov 16 Fresenius Medical Care AG & Co. KGaA to Report Q2, 2023 Results on Aug 02, 2023
Second quarter 2022 earnings released: EPS: €0.50 (vs €0.75 in 2Q 2021) Aug 03
Fresenius Medical Care AG & Co. KGaA Revises Earnings Guidance for the Full Year 2022 Aug 03
Investor sentiment deteriorated over the past week Jul 28
Fresenius Medical Care AG & Co. KGaA Provides Earnings Guidance for the Second Half of 2022 Jul 28
Fresenius Medical Care AG & Co. KGaA to Report Q3, 2022 Final Results on Nov 09, 2022 May 15
First quarter 2022 earnings released: EPS: €0.54 (vs €0.85 in 1Q 2021) May 08
Upcoming dividend of €1.35 per share May 06
Fresenius Medical Care Appoints Nwamaka (Amaka) Eneanya as Head of Strategy and Operations for the Company's Global Medical Office Apr 06
Fresenius Medical Care AG & Co. KGaA Proposes Dividend, Due on 17 May 2022 Apr 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24 Fresenius Medical Care Ag & Co. Kgaa Provides Earnings Forecast for the Year 2022
Fresenius Medical Care Reportedly in Talks to Buy Dmed Diyaliz Jan 27
Fresenius Medical Care AG & Co. KGaA Launches New Mobile App to Empower and Engage Nurses Dec 21
Third quarter 2021 earnings released: EPS €0.93 (vs €1.21 in 3Q 2020) Nov 04
Second quarter 2021 earnings released: EPS €0.75 (vs €1.20 in 2Q 2020) Aug 03
Independent Member of Supervisory Board has left the company May 27
Fresenius Medical Care Approves Dividend for the Fiscal Year 2020 May 21 Shareholder Returns 1FME IT Healthcare IT Market 7D -1.3% -2.4% -0.9% 1Y 18.0% 4.0% 10.7%
See full shareholder returns
Return vs Market: 1FME exceeded the Italian Market which returned 10.8% over the past year.
Price Volatility Is 1FME's price volatile compared to industry and market? 1FME volatility 1FME Average Weekly Movement 3.8% Healthcare Industry Average Movement 4.2% Market Average Movement 4.3% 10% most volatile stocks in IT Market 7.8% 10% least volatile stocks in IT Market 2.5%
Stable Share Price: 1FME has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: 1FME's weekly volatility (4%) has been stable over the past year.
About the Company Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Show more Fresenius Medical Care AG Fundamentals Summary How do Fresenius Medical Care's earnings and revenue compare to its market cap? 1FME fundamental statistics Market cap €13.22b Earnings (TTM ) €658.94m Revenue (TTM ) €19.24b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1FME income statement (TTM ) Revenue €19.24b Cost of Revenue €14.40b Gross Profit €4.84b Other Expenses €4.18b Earnings €658.94m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) 2.25 Gross Margin 25.14% Net Profit Margin 3.43% Debt/Equity Ratio 49.4%
How did 1FME perform over the long term?
See historical performance and comparison Dividends
2.6% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 01:24 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Martin Schnee AlphaValue Brian Williams Avondale Partners Olav Zilian Baader Helvea Equity Research
Show 56 more analysts